Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer

NCT04080804 is registered in ClinicalTrials.gov with Dan Zandberg as lead sponsor.

NCT NCT04080804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04080804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer
Lead sponsor
Dan Zandberg
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 20, 2019
Completion date
April 13, 2028
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma (hnscc)